To date, immunogenic HLA-A2-specific BCMA-derived peptides allowed the ex vivo generation of highly functional BCMA-specific CD8+ CTLs, with effective killing of myeloma cells, characterized by IFN-γ, TNF-α and, IL-2 production [88]. This evidence concerns the gene CD8A and plasma cell myeloma.